European HealthTech this week is characterised by AI‑heavy care models preparing for the EU AI Act, continued investor focus on preventive and platform plays, and early‑stage funding/grant activity positioning startups for 2026–27 scale‑up. European MedTech this week is dominated by regulatory moves in Brussels, tightening timelines ahead of the 2026 MDR/IVDR and EUDAMED deadlines, alongside positioning by industry and investors for an “industrial maturity” phase rather than

European HealthTech this week is dominated by regulatory fine‑tuning around AI in devices, fresh EU‑level funding calls, and continued capital and grant focus on AI‑enabled care delivery and data platforms. European MedTech this week is being shaped by MDR/IVDR simplification moves, the hardening EUDAMED timetable, and EU‑level initiatives (including the Biotech Act and IHI Call 12) that favour data‑rich,

The biggest European MedTech developments this week centre on the EU’s proposed overhaul of MDR/IVDR, a broader Commission health package to boost innovation and resilience, and continued capital formation for MedTech and digital health scale‑ups.  Together these moves signal a more innovation‑friendly regulatory path and fresh growth funding for European MedTech heading into 2026.​